Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC-01 in healthy adults
NCT03832517Phase 1Terminated
- Sponsor
- Recida Therapeutics
- Start
- Apr 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RC-01 in gram-negative bacterial infections (4 arms), sponsored by Recida Therapeutics. Primary endpoint: Number of participants with a treatment-related adverse event. Started Apr 2019; status: terminated.
02
Drugs
RC-01
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT03832517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832517.